| NCT07187375 | Pharmacokinetics, Safety and Tolerability of Crinecerfont in Participants With Congenital Adrenal Hyperplasia Who Are Less Than 2 Years Old | NOT_YET_RECRUITING | PHASE2 | 2025-09-28 | 2029-10-04 | 2029-09-06 |
| NCT07105111 | A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor | RECRUITING | PHASE4 | 2025-08-29 | 2027-04 | 2027-04 |
| NCT07196501 | A Study to Evaluate the Maintenance Effect of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD) | RECRUITING | PHASE3 | 2025-08-18 | 2028-07 | 2028-07 |
| NCT07105098 | NBI-1117568-SCZ3030: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia | RECRUITING | PHASE3 | 2025-08-11 | 2027-11 | 2027-11 |
| NCT07114874 | NBI-1117568-SCZ3032: Long-Term Evaluation of NBI-1117568 in Adults With Schizophrenia | RECRUITING | PHASE3 | 2025-07-11 | 2031-12 | 2031-12 |
| NCT06963021 | NBI-1065845-MDD3026: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD) | RECRUITING | PHASE3 | 2025-05-30 | 2027-07 | 2027-07 |
| NCT06963034 | NBI-1117568-SCZ3029: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia | RECRUITING | PHASE3 | 2025-05-08 | 2027-10 | 2027-10 |
| NCT06966401 | Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD) | RECRUITING | PHASE3 | 2025-04-16 | 2030-05 | 2029-05 |
| NCT06911112 | NBI-1065845-MDD3025: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD) | RECRUITING | PHASE3 | 2025-03-31 | 2027-07 | 2027-07 |
| NCT06786624 | Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD) | RECRUITING | PHASE3 | 2025-01-22 | 2027-07 | 2027-07 |
| NCT06312189 | Long-term Study to Evaluate Safety and Tolerability of Valbenazine in Participants With Chorea Associated With Huntington Disease in Canada | ENROLLING_BY_INVITATION | PHASE3 | 2024-04-24 | 2026-04 | 2026-04 |
| NCT06267846 | A Study to Evaluate the Efficacy and Safety of NBI-1070770 in Adults With Major Depressive Disorder | ACTIVE_NOT_RECRUITING | PHASE2 | 2024-03-20 | 2025-12 | 2025-09 |
| NCT05859698 | Study of the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Participants With Tardive Dyskinesia | COMPLETED | PHASE4 | 2023-05-25 | 2024-12-27 | 2024-12-27 |
| NCT05654870 | Study to Evaluate the Efficacy, Safety, and Tolerability of Valbenazine as an Adjunctive Treatment for Schizophrenia | TERMINATED | PHASE3 | 2023-01-05 | 2023-11-08 | 2023-11-08 |
| NCT05493293 | Extension Study to Evaluate the Safety and Tolerability of NBI-921352 When Used With Anti-seizure Medications in Adults With Focal Onset Seizures | TERMINATED | PHASE2 | 2022-11-09 | 2024-03-11 | 2024-03-11 |
| NCT05545111 | Efficacy, Safety, Tolerability, and Pharmacokinetics of NBI-1117568 in Adults With Schizophrenia | COMPLETED | PHASE2 | 2022-10-04 | 2024-07-10 | 2024-07-10 |
| NCT05226780 | Extension Study to Evaluate How Safe and Tolerable NBI-921352 is as an Adjunctive Therapy for Participants With SCN8A-DEE | ACTIVE_NOT_RECRUITING | PHASE2 | 2022-07-12 | 2026-03 | 2026-03 |
| NCT05301894 | Extension Study to Evaluate NBI-827104 in Pediatric Participants With Epileptic Encephalopathy With Continuous Spike-and-Wave During Sleep | TERMINATED | PHASE2 | 2022-06-07 | 2025-01-27 | 2025-01-27 |
| NCT05206513 | Study to Assess the Efficacy, Safety, and Tolerability of Valbenazine for the Treatment of Dyskinesia Due to Cerebral Palsy | ACTIVE_NOT_RECRUITING | PHASE3 | 2022-04-15 | 2026-06 | 2025-12 |
| NCT05203341 | Study to Assess the Efficacy and Safety of NBI-1065845 in Adults With Major Depressive Disorder (MDD) | COMPLETED | PHASE2 | 2022-02-21 | 2024-02-21 | 2024-01-10 |
| NCT04873869 | Study to Evaluate NBI-921352 as Adjunctive Therapy in Subjects With SCN8A Developmental and Epileptic Encephalopathy Syndrome (SCN8A-DEE) | TERMINATED | PHASE2 | 2022-01-31 | 2023-03-17 | 2023-03-17 |
| NCT05182476 | Study to Evaluate the Efficacy, Safety, and Tolerability of Luvadaxistat in Participants With Cognitive Impairment Associated With Schizophrenia | TERMINATED | PHASE2 | 2021-12-07 | 2024-10-14 | 2024-06-28 |
| NCT05165394 | Study to Evaluate the Efficacy and Safety of Once-Weekly Oral NBI-1065846 in the Treatment of Anhedonia in MDD | COMPLETED | PHASE2 | 2021-11-30 | 2023-09-13 | 2023-07-07 |
| NCT05110157 | Journey Study: Evaluate the Efficacy, Safety, and Tolerability of Valbenazine as Adjunctive Treatment for Schizophrenia | COMPLETED | PHASE3 | 2021-11-29 | 2025-02-18 | 2025-02-04 |
| NCT05159908 | A Study to Investigate How Effective, Safe and Tolerable the Drug NBI-921352 is When Used With Anti-seizure Medications in Adults With Focal Onset Seizures | COMPLETED | PHASE2 | 2021-11-08 | 2023-08-21 | 2023-08-21 |
| NCT04806451 | Global Safety and Efficacy Registration Study of Crinecerfont in Pediatric Participants With Classic Congenital Adrenal Hyperplasia (CAHtalyst Pediatric Study) | ACTIVE_NOT_RECRUITING | PHASE3 | 2021-06-25 | 2027-08 | 2023-03-10 |
| NCT04625101 | Efficacy, Safety, Tolerability, and Pharmacokinetics of NBI-827104 in Pediatric Subjects With Epileptic Encephalopathy With Continuous Spike-and-Wave During Sleep | COMPLETED | PHASE2 | 2021-04-26 | 2022-10-11 | 2022-08-08 |
| NCT04880616 | Safety, Efficacy, and Tolerability of NBI-827104 for the Treatment of Essential Tremor | COMPLETED | PHASE2 | 2021-04-20 | 2022-06-08 | 2022-05-25 |
| NCT04490915 | Global Safety and Efficacy Registration Study of Crinecerfont for Congenital Adrenal Hyperplasia | ACTIVE_NOT_RECRUITING | PHASE3 | 2020-12-16 | 2027-08 | 2023-07-19 |
| NCT04400331 | Open-Label Rollover Study for Continuing Valbenazine Administration for the Treatment of Chorea Associated With Huntington Disease | ACTIVE_NOT_RECRUITING | PHASE3 | 2020-09-18 | 2026-03 | 2026-03 |
| NCT04234672 | A Study to Assess Absolute Bioavailability (ABA) of TAK-831 and to Characterize Mass Balance, Pharmacokinetics (PK), Metabolism, and Excretion of [14C]TAK-831 in Male Healthy Participants | COMPLETED | PHASE1 | 2020-02-17 | 2020-04-04 | 2020-04-04 |
| NCT04045145 | Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NBI-74788 (Crinecerfont) in Pediatric Participants With Congenital Adrenal Hyperplasia | COMPLETED | PHASE2 | 2019-12-12 | 2021-07-02 | 2021-07-02 |
| NCT04102579 | Efficacy, Safety, and Tolerability of Valbenazine for the Treatment of Chorea Associated With Huntington Disease | COMPLETED | PHASE3 | 2019-11-13 | 2021-10-26 | 2021-10-15 |
| NCT03891862 | Persistence of Effect and Safety of Valbenazine for the Treatment of Tardive Dyskinesia | COMPLETED | PHASE4 | 2019-03-18 | 2020-01-30 | 2019-12-23 |
| NCT03792672 | A Study to Evaluate Central Nervous System (CNS) Pharmacodynamic Activity of TAK-653 in Healthy Participants Using Transcranial Magnetic Stimulation (TMS) | COMPLETED | PHASE1 | 2019-02-11 | 2019-06-18 | 2019-05-15 |
| NCT03706469 | A Study to Evaluate the Relative Bioavailability (BA) and Effect of Food on TAK-831 Tablet Formulations in Healthy Participants | COMPLETED | PHASE1 | 2018-10-18 | 2018-12-22 | 2018-12-11 |
| NCT03562494 | VY-AADC02 for Parkinson's Disease With Motor Fluctuations (RESTORE-1) | COMPLETED | PHASE1 | 2018-10-17 | 2024-10-30 | 2024-10-30 |
| NCT03732534 | Rollover Study for Continuing NBI-98854 Administration in Pediatric Subjects With Tourette Syndrome | TERMINATED | PHASE2 | 2018-10-17 | 2019-02-18 | 2019-02-18 |
| NCT03687684 | Phase 1 Study of TAK-831 in Healthy Adult Asian Subjects | COMPLETED | PHASE1 | 2018-10-09 | 2019-06-19 | 2019-06-09 |
| NCT03698331 | The Potential for Clinical Dependence and Withdrawal Symptoms Associated With Valbenazine | COMPLETED | PHASE4 | 2018-09-14 | 2019-04-03 | 2019-04-03 |
| NCT03530293 | Safety and Efficacy of NBI-98854 in Pediatric Subjects With Tourette Syndrome | TERMINATED | PHASE2 | 2018-04-17 | 2019-07-16 | 2019-07-16 |
| NCT03525886 | Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NBI-74788 in Adults With Congenital Adrenal Hyperplasia | COMPLETED | PHASE2 | 2018-04-10 | 2020-04-07 | 2020-04-07 |
| NCT03444038 | Open-Label Safety and Tolerability Study of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome | COMPLETED | PHASE2 | 2018-02-08 | 2019-07-12 | 2019-07-12 |
| NCT03496870 | A Study of the Pharmacokinetics, Pharmacodynamics, and Safety of Opicapone in Subjects With Parkinson's Disease Taking Levodopa. | COMPLETED | PHASE1 | 2018-02-08 | 2018-07-02 | 2018-07-02 |
| NCT03359785 | A Study to Evaluate Multiple Oral Doses of Luvadaxistat in Adults With Schizophrenia | COMPLETED | PHASE2 | 2018-01-10 | 2020-12-21 | 2020-12-21 |
| NCT03382639 | A Study to Evaluate 3 Dose Levels of Luvadaxistat of Adults With Negative Symptoms of Schizophrenia | COMPLETED | PHASE2 | 2018-01-04 | 2021-01-12 | 2020-12-29 |
| NCT03319953 | A Randomized, Double-Blind, Placebo Controlled, Two-Period Cross-Over, Proof of Activity Study to Evaluate the Effects of TAK-041 on Motivational Anhedonia as Add-On to Antipsychotics in Participants With Stable Schizophrenia | COMPLETED | PHASE2 | 2017-12-21 | 2019-11-06 | 2019-09-11 |
| NCT03214588 | Efficacy, Tolerability, and Pharmacokinetics of Multiple Doses of Oral TAK-831 in Adults With Friedreich Ataxia | COMPLETED | PHASE2 | 2017-11-08 | 2018-12-27 | 2018-12-27 |
| NCT03325010 | Safety, Tolerability, and Efficacy of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome | COMPLETED | PHASE2 | 2017-10-05 | 2018-11-16 | 2018-11-01 |
| NCT03224325 | A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Escalating Multiple Doses of TAK-831 in Healthy Participants | COMPLETED | PHASE1 | 2017-07-21 | 2018-09-09 | 2018-09-09 |
| NCT03065192 | Safety and Efficacy Study of VY-AADC01 for Advanced Parkinson's Disease | COMPLETED | PHASE1 | 2017-05-11 | 2021-08-10 | 2021-08-10 |
| NCT03101293 | A Study to Evaluate the Effect of Food on the Pharmacokinetics of TAK-831 Tablet Formulation | COMPLETED | PHASE1 | 2017-04-04 | 2017-05-26 | 2017-05-19 |
| NCT02959892 | A Single-Dose Positron Emission Tomography (PET) Study to Determine the Effect of TAK-041 on Amphetamine-Induced Dopamine Release in the Central Nervous System (CNS) | COMPLETED | PHASE1 | 2016-12-05 | 2017-08-23 | 2017-05-30 |
| NCT02879578 | Safety and Tolerability Study of NBI-98854 for the Treatment of Subjects With Tourette Syndrome | COMPLETED | PHASE2 | 2016-07-25 | 2017-11-01 | 2017-11-01 |
| NCT02736955 | Rollover Study for Continuing Valbenazine (NBI-98854) Administration for the Treatment of Tardive Dyskinesia | COMPLETED | PHASE3 | 2016-06-13 | 2017-06-30 | 2017-06-30 |
| NCT02748694 | Phase 1 TAK-041 First-in-Human Safety, Tolerability, and Pharmacokinetics Study | COMPLETED | PHASE1 | 2016-05-09 | 2019-09-22 | 2019-09-22 |
| NCT02679079 | Safety and Efficacy Study of NBI-98854 in Children and Adolescents With Tourette Syndrome | COMPLETED | PHASE2 | 2016-03-23 | 2017-04-14 | 2017-04-14 |
| NCT02716987 | Study to Determine D-amino Acid Oxidase Brain Enzyme Occupancy of TAK-831 After Single-dose Oral Administration | COMPLETED | PHASE1 | 2016-03-21 | 2016-08-30 | 2016-08-30 |
| NCT02581865 | Safety and Efficacy Study of NBI-98854 in Adults With Tourette Syndrome | COMPLETED | PHASE2 | 2015-11 | 2016-12 | 2016-12 |
| NCT02566759 | A TAK-831-1001, Single and Multiple Rising Dose Study in Healthy Participants | TERMINATED | PHASE1 | 2015-09-23 | 2016-07-12 | 2016-06-09 |
| NCT02561156 | TAK-653 Escalating Single and Multiple Dose Study in Healthy Participants | COMPLETED | PHASE1 | 2015-08-26 | 2017-09-23 | 2017-09-11 |
| NCT02405091 | Safety and Tolerability Study of NBI-98854 for the Treatment of Tardive Dyskinesia | COMPLETED | PHASE3 | 2015-03 | 2017-03 | 2017-03 |
| NCT02349503 | Safety, Pharmacokinetics and Pharmacodynamics of NBI-77860 in Adolescent Females With Congenital Adrenal Hyperplasia | WITHDRAWN | PHASE1 | 2015-02 | 2015-10 | 2015-10 |
| NCT02274558 | A Phase 3 Study of NBI-98854 for the Treatment of Tardive Dyskinesia | COMPLETED | PHASE3 | 2014-10 | 2016-07 | 2015-09 |
| NCT02256475 | Safety, Pharmacokinetics, and Pharmacodynamics of NBI-98854 in Children and Adolescents With Tourette Syndrome | COMPLETED | PHASE1 | 2014-09 | 2015-12 | 2015-11 |
| NCT01973543 | Safety Study of AADC Gene Therapy (VY-AADC01) for Parkinson's Disease | COMPLETED | PHASE1 | 2013-10 | 2020-01-24 | 2020-01-24 |
| NCT01916993 | Safety, Tolerability, and Pharmacokinetics of a Single Dose of NBI-98854 in Subjects With Mild,Moderate, or Severe Hepatic Insufficiency | COMPLETED | PHASE1 | 2013-08 | 2013-12 | 2013-12 |
| NCT01910480 | Study to Assess the Effect of Ketoconazole on the Pharmacokinetics of NBI-98854 in Healthy Subjects | COMPLETED | PHASE1 | 2013-07 | 2013-08 | 2013-08 |
| NCT01733121 | NBI-98854 Dose Titration Study for the Treatment of Tardive Dyskinesia | COMPLETED | PHASE2 | 2012-12 | 2013-12 | 2013-12 |
| NCT01688037 | NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder (KINECT Study) | COMPLETED | PHASE2 | 2012-09 | 2013-10 | 2013-09 |
| NCT01393600 | NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder | COMPLETED | PHASE2 | 2011-08 | 2012-02 | 2012-02 |
| NCT01267188 | Efficacy and Safety of NBI-98854 in Subjects With Tardive Dyskinesia | COMPLETED | PHASE2 | 2011-01 | 2011-03 | 2011-03 |
| NCT00525941 | An Exploratory Study of NBI-34060 Capsules and Next Day Functioning | WITHDRAWN | PHASE3 | 2007-09 | 2008-01 | 2008-01 |
| NCT00232167 | Study Of Indiplon/Placebo With Sertraline In Insomnia Co-Existing With Depression | TERMINATED | PHASE3 | 2005-11 | 2006-04 | |
| NCT00079495 | Evaluation of an Altered Peptide Ligand (NBI-5788) in Patients With Relapsing Multiple Sclerosis (MS) | COMPLETED | PHASE2 | 2003-07 | 2005-04 | |
| NCT00873561 | A Study to Evaluate NBI-6024 in Adult and Adolescent Patients With New Onset of Type 1 Diabetes Mellitus | COMPLETED | PHASE1 | 2001-12 | 2006-07 | 2006-04 |